Cell Therapy Manufacturing: The $ 8 Billion+ Growth Opportunity

Cell Therapy Manufacturing market has gained significant attention in the overall biopharmaceutical industry. The personalized nature of these cell therapies options render them highly specific and, according to a number of clinical studies, safe and efficacious. Around 20 such therapies have been approved so far; recent approvals include Alofisel® (2018), YESCARTA® (2017) and Kymriah® (2017). It is also worth highlighting that over 500 therapy candidates are in different stages of clinical development by cell therapy manufacturing companies and are being evaluated in more than 1,000 active clinical studies across various regions of the globe. The growing number of cell therapy candidates, coupled to their rapid progression through various phases of clinical development, continues to create an increasing demand for facilities that offer cell therapy manufacturing services for these complex therapies.


Presently, over 145 organizations are actively involved in the GMP manufacturing of various types of genetically modified cells that are intended for therapeutic use.


The competitive landscape features the presence of industry and non-industry players, having the capability to produce various types of cell therapies including CAR T cell therapy at different scales of operation

Around 60% of the industry players are involved in manufacturing of cell therapy including immune cells, stem cells and others. Additionally, majority of cell therapies are currently in clinical stage.

Stem cells and immune cells are presently the major focus; there are many T-cell based candidates under development, most of which are in clinical stages.


The installed global cell therapy manufacturing capacity is currently estimated to be around 1.1 billion square feet; this capacity is well distributed across various geographies.


The US and EU, with relatively more number of manufacturing facilities, are the key hubs for cell-based therapy production.


Over 150 partnerships indicate an increasing activity in this domain; players are actively entering into collaborations focused on diverse types of cell therapies

Various industry and non-industry players have inked partnership focusing on cell therapy manufacturing. Around 65% of the partnerships were signed for immune cells.

Integration of automation technologies is anticipated to further augment production processes, offering favorable bench-to-clinic timelines and making such therapies more affordable.


Overall, the market is poised to grow at a steady pace and has over USD 8 billion potential; the opportunity is likely to be spread across different types of cell therapies.


In the short-term, clinical products will drive the market; however, in the long term, backed by commercial scale production, the US and EU are likely to capture over 75% share

The cell therapy manufacturing market is widely distributed across various segments. As per Roots Analysis, North America and Europe is likely to capture the largest market share

To learn more, please click Cell Therapy Manufacturing market. For any queries / suggestions, please do not hesitate to contact us at sales@rootsanalysis.com

Our Social Media Platform

Web: https://www.rootsanalysis.com/

LinkedIn: https://in.linkedin.com/company/roots-analysis

Twitter: https://twitter.com/RootsAnalysis